In a 16-year-old female patient presenting with refractory, locally recurrent TFE3-fusion-positive tRCC with lung metastases, treatment with cabozantinib led to prompt and durable disease control. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.